Cart is empty
View Cart
Subtotal: $0.00
JOIN NOW!
Featured Image

In Reversal, Amylyx ALS Drug Receives FDA Advisory Committee Support

  • Posted by ISPE Boston
  • On September 9, 2022
Amylyx Pharmaceuticals announced today that the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 7 to 2 that the available evidence of effectiveness is sufficient to support approval of the drug the company has developed for the treatment of ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig’s disease. The committee’s decision was […]
Read More
 
 Featured Image

MassBio Reports MA Biopharma Raised $5.1 Billion

  • Posted by ISPE Boston
  • On September 8, 2022
The 2022 Industry Snapshot newly released  by the Massachusetts Biotechnology Council (MassBio) shows significant growth across the life sciences industry in 2021 in both workforce and real estate and reveals resilience in the face of some notable headwinds. Venture capital funding of the biopharma industry remains strong in 2022 despite a downturn in biopharma stock […]
Read More
 
 Featured Image

Novo Nordisk to Buy Forma Therapeutics for $1.1 Billion

  • Posted by ISPE Boston
  • On September 8, 2022
Watertown-based Forma Therapeutics, a clinical-stage biopharma focused on sickle cell disease (SCD) and rare blood disorders, is being acquired by Novo Nordisk for $1.1 billion. The acquisition includes Forma’s lead development candidate, etavopivat, and is aligned with Novo Nordisk’s strategy to complement and accelerate its scientific presence and pipeline in hemoglobinopathies, a group of disorders in which […]
Read More
 
 Featured Image

A wet but fun day at the Summer Golf Tournament

  • Posted by Paul Sullivan
  • On September 7, 2022
Two weeks ago, on Monday, August 22nd, ISPE Members and guests gathered at the beautiful Kernwood Country Club in Salem, MA for our annual Summer Golf Tournament. We had 32 foursomes playing, and sold out within 3 hours of launching registration! Despite the very wet weather, our teams had fun catching up with each other. […]
Read More
 
 Featured Image

Chapter Member Anniversaries: September 2022

  • Posted by ISPE Boston
  • On September 6, 2022
Please congratulate the following members celebrating milestone anniversaries in September 2022.  Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Edwin Harmon, PCI/ LSNE Hooman Sajedian, Pfizer Inc Lawrence Weiner, Enzyvant Therapeutics Jeffrey Werner, Retired Armand Mintanciyan Douglas Grevatt, Boehringer Ingelheim Pharma Gordon Brailsford, Cresa Boston Donna DeFreitas, […]
Read More
 
 Featured Image

Welcome New Members August 2022!

  • Posted by ISPE Boston
  • On September 6, 2022
We would like to introduce the Members who joined ISPE in August 2022, welcome them to the Chapter and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]
Read More
 
 Featured Image

Congratulations to our 2022 Scholarship Winners!

  • Posted by ISPE Boston
  • On August 24, 2022
The ISPE Boston Chapter Scholarship Foundation is proud to award a total of $40,000 in scholarships to the winners of the 2022 round of the Joel Goldenberg Memorial Scholarship Program. This brings the total awarded scholarships to date to $311K! What an amazing way to help graduating high school seniors prepare for their future in […]
Read More
 
 Featured Image

Orna Therapeutics oRNA Therapies Get Nod from Merck

  • Posted by ISPE Boston
  • On August 18, 2022
Cambridge startup Orna Therapeutics has announced a collaboration agreement with Merck to discover, develop, and commercialize multiple programs pioneering a new investigational class of engineered circular RNA (oRNA) therapies, including vaccines and therapeutics in the areas of infectious diseases and oncology. Under the terms of the agreement, Merck will make an upfront payment to Orna […]
Read More
 
 Featured Image

bluebird bio Wins FDA Approval of First Gene Therapy for Beta-Thalassemia

  • Posted by ISPE Boston
  • On August 18, 2022
Somerville biotech bluebird bio has received approval from the FDA for Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Zynteglo was reviewed under Priority Review, and bluebird received a Priority Review […]
Read More